IDEXX Laboratories, Inc. research snapshot
IDXX AI stock analysis currently reads IDEXX Laboratories as a high-quality veterinary diagnostics and software company with strong recurring CAG diagnostics growth, high margins, and a durable installed-base model, offset by a rich valuation and still-weak broader veterinary visit backdrop. At the July 8, 2026 data cutoff, IDXX traded near $570.25 with an independently verified market capitalization of about $44.98 billion. This page uses scenarios, technical levels, and source-backed facts. It is informational research, not investment advice.
Current price
$570.25
Market cap
$44.98 billion
AI score
78 / 100
Rating
High-quality veterinary diagnostics compounder with premium valuation risk
Trend status
Recovering short-term, still below the 200-day moving average
Data cutoff (updated weekly)
July 8, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | IDEXX sells veterinary diagnostics, reference lab services, software, imaging, water testing, and livestock diagnostics, with the core CAG model tied to recurring consumables and lab testing. | High |
| Moat | The moat comes from installed instruments, test menus, reference lab scale, clinical workflow integration, data, service relationships, and high customer retention. It is strongest in companion animal diagnostics. | High |
| Management | Mike Erickson became President and CEO on May 12, 2026, while former CEO Jay Mazelsky moved to Executive Chair, creating a planned internal transition but still a leadership handoff to monitor. | Medium-high |
| Financial trend | FY2025 revenue was about $4.304 billion and FY2025 net income was about $1.059 billion. Q1 2026 revenue rose 14% as reported to $1.141 billion, with diluted EPS of $3.47. | High |
| Valuation | At $570.25, IDXX traded near 41.96x TTM EPS, 29.04x book value, and 41.53x free cash flow per share, so even a great business needs sustained growth to justify the price. | High |
| Technical trend | The stock was slightly above the 50-day moving average near $555.82 but below the 200-day moving average near $627.29, signaling a short-term rebound inside a still-damaged longer-term trend. | Medium |
| Risk level | Key risks are premium valuation, weaker veterinary visits, slower instrument placements, new product adoption risk, competitive diagnostics pressure, foreign exchange, buyback timing, and leadership transition execution. | Medium-high |
| AI confidence | High for descriptive research and calculations. Lower for exact return outcomes because a small change in growth expectations or PE multiple can move IDXX materially. | High data confidence |
| Investment certainty | Medium certainty. The business quality is high, but margin of safety is not obvious unless growth and returns on innovation remain strong for several years. | Medium |
IDXX AI stock forecast
The IDXX AI stock forecast uses scenario math around the $570.25 quote and the midpoint of management 2026 EPS guidance near $14.675. The audited three-year framework produced a bearish area near $462, a base area near $703, and a bullish area near $913 before any buyback effect. The range is wide because IDXX combines high business quality with a valuation that is sensitive to growth and multiple assumptions.
$850 to $940
More likely if EPS compounds near 14% annually, CAG Diagnostics recurring revenue sustains high-single-digit to low-double-digit organic growth, InVue Dx and Cancer Dx adoption deepen the installed base, margins expand, and the market continues to value IDXX near a premium 42x earnings multiple.
$670 to $730
More likely if EPS compounds near 10% annually, veterinary visit trends gradually improve, pricing and volume support recurring diagnostics, Water and LPD remain smaller stabilizers, and investors value IDXX around 36x forward earnings.
$430 to $490
More likely if vet visits stay weak, instrument placements or new diagnostic menus disappoint, operating margin stalls, currency turns adverse, the CEO transition distracts execution, and the market compresses IDXX toward 28x earnings.
IDXX AI technical analysis
IDXX AI technical analysis is mixed as of the July 8, 2026 cutoff. The stock had recovered above its 50-day moving average but remained below the 200-day moving average, while RSI was neutral near 56. Technical levels should be refreshed with live chart data before trading.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $570.25 | July 7, 2026 close used for market cap and valuation math at the July 8 data cutoff. |
| Near support | $555 to $560 | The 50-day moving average area is the first support band after the recent rebound. |
| Deeper support | $515 to $525 | The lower 52-week range area is the deeper downside reference if the rebound fails. |
| Near resistance | $600 to $627 | The first resistance zone sits between round-number supply and the 200-day moving average. |
| 50-day moving average | About $555.82 | Price was above this intermediate trend gauge, which supports the short-term recovery. |
| 200-day moving average | About $627.29 | Price was below this long-term trend gauge, so the broader chart has not fully repaired. |
| Momentum | RSI about 56.14 | Momentum was neutral to modestly positive, not an overbought reading by itself. |
| Volume | About 679,000 average daily shares | Breakouts above resistance should be judged against recent average volume because low-volume rebounds can fade. |
| Volatility | Beta about 1.55 | StockAnalysis showed beta above the market average, so position sizing matters around earnings and guidance. |
| Invalidation | Close below $555, then $515 | A close below the 50-day moving average would weaken the rebound. A break into the low $500s would signal a deeper failed setup. |
IDXX AI trading strategy
The IDXX AI trading strategy is a rules-based research framework for a high-quality diagnostics compounder trading at a premium multiple. It is not personal advice and should be paired with live quotes, filings, position sizing, and risk controls.
Watch for IDXX to hold above the 50-day moving average near $556 and reclaim the 200-day moving average near $627 with volume confirmation, stable guidance, and no deterioration in CAG Diagnostics recurring revenue.
A close below about $555 or a failed move at the 200-day moving average should invalidate the short-term setup.
If IDXX pulls back toward the low $500s without a new earnings, product, or veterinary demand shock, compare the price with 2026 EPS guidance, recurring diagnostics growth, and the three-scenario valuation range.
Do not average down without a defined loss limit because high-multiple compounders can keep derating when growth expectations fall.
Track CAG Diagnostics recurring revenue, installed premium instruments, IDEXX VetLab consumables, reference lab volumes, InVue Dx placements, Cancer Dx adoption, Water growth, LPD growth, operating margin, free cash flow, buybacks, and CEO transition execution.
Reduce confidence if EPS growth relies mainly on buybacks or multiple expansion instead of recurring diagnostics volume, price realization, innovation adoption, and operating leverage.
Investment research summary
IDEXX helps veterinarians, animal health customers, and water testing users make faster diagnostic decisions. Customers pay for reliable instruments, consumables, reference lab testing, software workflows, and clinical insight that can improve care and practice productivity.
The moat is strongest in the companion animal ecosystem: installed analyzers pull consumables, reference labs add scale and trust, software supports workflow stickiness, and new test menus make the platform more valuable. It narrows if customers delay visits, competitors match clinical value, or instrument adoption slows.
The thesis fails if veterinary visit weakness becomes structural, pet owners trade down on diagnostics, new platforms underperform, pricing power fades, regulatory or quality issues hit confidence, or the stock keeps a premium multiple while EPS growth slows.
IDEXX executed a planned CEO succession in May 2026, with Mike Erickson stepping up from diagnostics leadership and Jay Mazelsky becoming Executive Chair. The transition preserves institutional knowledge, but investors still need evidence that innovation pace and commercial execution remain intact.
Pet healthcare benefits from humanization of pets, aging pet populations, higher diagnostic standards, and clinic workflow digitization. The trend is favorable, but near-term veterinary visits and consumer affordability can still pressure volume.
IDXX is priced like a rare compounder. The margin of safety depends less on balance-sheet survival and more on whether recurring diagnostics growth, margin expansion, and innovation can keep earnings compounding fast enough to support a premium PE.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| IDXX price | $570.25 close on July 7, 2026 | StockAnalysis market data snapshot | July 8, 2026 |
| Market capitalization | $44.98 billion, verified as $570.25 x 78.88 million shares with 0.00% variance | financial_rigor.py market cap verification | July 8, 2026 |
| Shares outstanding | 78.88 million shares | StockAnalysis statistics | July 8, 2026 |
| FY2025 revenue | $4.304 billion, cross-validated against IDEXX Form 10-K and Macrotrends | IDEXX 2025 Form 10-K and Macrotrends | July 8, 2026 |
| FY2025 net income | $1.059 billion from IDEXX Form 10-K; StockAnalysis TTM after Q1 2026 was about $1.10 billion | IDEXX 2025 Form 10-K and StockAnalysis financials | July 8, 2026 |
| Q1 2026 revenue and EPS | $1.141 billion revenue and $3.47 diluted EPS | IDEXX Q1 2026 earnings release | July 8, 2026 |
| 2026 guidance | $4.675 billion to $4.760 billion revenue and $14.45 to $14.90 EPS | IDEXX Q1 2026 earnings release | July 8, 2026 |
| CAG Q1 2026 revenue | $1.054 billion net CAG revenue, up 14.6% as reported and 11.6% organic | IDEXX Q1 2026 Form 10-Q | July 8, 2026 |
| Cash and debt | $200.53 million cash and cash equivalents; $1.11 billion total debt; net cash position of negative $904.92 million | IDEXX Q1 2026 Form 10-Q and StockAnalysis balance sheet | July 8, 2026 |
| Valuation snapshot | 41.96x TTM PE, 29.04x book value, 41.53x P/FCF, and 2.41% FCF yield from audited inputs | financial_rigor.py valuation verification | July 8, 2026 |
| Technical snapshot | 50-day moving average about $555.82, 200-day moving average about $627.29, RSI about 56.14, beta about 1.55 | StockAnalysis statistics | July 8, 2026 |
| CEO succession | Mike Erickson became President and CEO effective May 12, 2026; Jay Mazelsky transitioned to Executive Chair | IDEXX CEO succession release | July 8, 2026 |
This IDXX AI stock analysis is an informational research tool only. It is not investment advice, a recommendation, or a guarantee of future returns. Forecast scenarios are based on available public data as of July 8, 2026 and may be wrong if IDEXX fundamentals, veterinary visit trends, diagnostics adoption, operating margins, competition, currency, leadership execution, interest rates, or market valuation change.
